

1 Olivia M. Kim, State Bar No. 228382
WILSON SONSINI GOODRICH & ROSATI
2 Professional Corporation
633 West Fifth Street, Suite 1550
3 Los Angeles, CA 90071-2027
Telephone: (323) 210-2900
4 Facsimile: (866) 974-7329
Email: okim@wsgr.com

5 Attorneys for Amici Curiae American Hospital
6 Association, Association of American Medical
Colleges, and California Hospital Association
7
8
9

10 **SUPERIOR COURT OF THE STATE OF CALIFORNIA**
11 **COUNTY OF LOS ANGELES**

12 PASADENA HOSPITAL ASSOCIATION)	CASE NO. 21STCP00978
LTD. d/b/a HUNTINGTON HOSPITAL, and)	
13 CEDARS-SINAI HEALTH SYSTEM,)	[Assigned for all purposes to the Hon. James
)	Chalfant, Dept. 85]
14 Petitioners/Plaintiffs,)	
)	APPLICATION FOR LEAVE TO FILE
15 v.)	AMICUS CURIAE BRIEF BY THE
)	AMERICAN HOSPITAL
16 CALIFORNIA DEPARTMENT OF JUSTICE,)	ASSOCIATION, ASSOCIATION OF
and ROB BONTA, in his official capacity as)	AMERICAN MEDICAL COLLEGES,
17 Attorney General of California,)	AND CALIFORNIA HOSPITAL
)	ASSOCIATION AND [PROPOSED]
18 Respondents/Defendants.)	BRIEF IN SUPPORT OF PETITIONERS
)	
19)	Action Filed: March 30, 2021

20
21
22
23
24
25
26
27
28

1 **APPLICATION FOR LEAVE TO FILE AMICUS CURIAE BRIEF**

2 *Amici curiae* the American Hospital Association, Association of American Medical
3 Colleges, and California Hospital Association respectfully apply to this Court for permission to
4 file the attached 10-page brief in support of Petitioners Pasadena Hospital Association Ltd.,
5 operating Huntington Memorial Hospital, and Cedars-Sinai Health System and their petition for
6 writ of mandate. *Amici* respectfully contend that this brief would assist the Court in deciding this
7 matter. *See* Calif. R. Court 8.200(c)(2); Calif. R. Court 8.882(d). Although the rules governing
8 trial court proceedings are silent regarding the criteria for filing amicus briefs, individuals and
9 entities may file such briefs with the Court’s permission. *See, e.g.,* In re Veterans’ Industries, Inc.
10 (1970) 8 Cal. App. 3d 902, 924-25.

11 **STATEMENT OF INTEREST**

12 The American Hospital Association (“AHA”) is a national organization that represents
13 nearly 5,000 hospitals, healthcare systems, networks, and other providers of care, including 314
14 members in California, as well as 43,000 individual members. AHA members are committed to
15 improving the health of the communities that they serve and to helping ensure that care is available
16 to and affordable for all Americans. The AHA provides extensive education for health care leaders
17 and is a source of valuable information and data on health care issues and trends. It ensures that
18 members’ perspectives and needs are heard and addressed in national health-policy development,
19 legislative and regulatory debates, and judicial matters.

20 The Association of American Medical Colleges (“AAMC”) is a national, not-for-profit
21 association that represents and serves all 155 accredited U.S. medical schools (including the 13
22 schools in California), more than 400 major teaching hospitals and health systems (including 30
23 members in California), and more than 70 academic societies. Through these institutions and
24 organizations, the AAMC represents 179,000 faculty members, 92,000 medical students, and
25 140,000 resident physicians. The AAMC leads and serves the academic medicine community to
26 improve the health of people everywhere. The AAMC is dedicated to transforming health through
27 medical education, health care, medical research, and community collaborations. In addition, one
28 of the AAMC’s core missions is to advocate on behalf of its members and patients in connection

1 with national health-policy matters.

2 The California Hospital Association (“CHA”) is a nonprofit organization dedicated to
3 representing the interests of California hospitals and the patients they serve. CHA represents more
4 than 400 acute care hospital and health system members and 94 percent of the patient beds in
5 California, including general acute care hospitals, rural hospitals, psychiatric hospitals, academic
6 medical centers, county hospitals, investor-owned hospitals, and multi-hospital health systems.
7 These hospitals furnish vital health care services to millions of our state’s citizens. CHA provides
8 its members with state and federal representation in the legislative, judicial, and regulatory arenas,
9 in an effort to improve health care quality, access, and coverage; promote health care reform and
10 integration; achieve adequate health care funding and contain costs; improve and update laws and
11 regulations; and maintain public trust in health care. CHA often participates as an *amicus curiae*
12 in cases that have a substantial impact on hospitals and health systems.

13 Within the rapidly changing healthcare sector, hospital mergers and affiliations often
14 provide significant benefits to patients and communities by allowing hospitals to lower their costs,
15 improve quality, and deliver more integrated and innovative care to communities. Many of the
16 AHA, AAMC, and CHA’s members are or will be parties to such mergers and affiliations,
17 including transactions in California; the *amici* therefore have a strong interest in ensuring that the
18 standards used to evaluate hospital transactions and affiliations comport with well-accepted
19 methods of economic analysis and market realities, rather than novel, speculative theories that lack
20 a sound legal, economic, or factual basis. Relatedly, the *amici* have an interest in ensuring that the
21 Office of the California Attorney General applies standards that are objective and predictable so
22 that their members can make informed judgments about pursuing transactions.

23 **HOW THIS BRIEF WILL ASSIST THE COURT**

24 *Amici* respectfully contend that the proposed brief will assist the Court by addressing two
25 issues: (1) how hospital transactions that involve community hospitals benefit patients and
26 communities in California and elsewhere; and (2) the analytical flaws and arbitrariness in the
27 approach that the Office of the California Attorney General and its retained economist use to
28 analyze the petitioners’ affiliation’s likely competitive effects and justify the onerous conditions

1 placed on the transaction. *Amici's* members have significant experience and expertise with
2 hospital mergers and affiliations, and the resulting cost savings and innovative care that such
3 transactions can produce.

4 **STATEMENT REGARDING PREPARATION OF THIS BRIEF**

5 No party or counsel in the pending case authored the proposed *amicus curiae* brief in whole
6 or in part, or made any monetary contribution intended to fund the preparation or submission of
7 the brief. No person or entity other than the proposed *amici* and their counsel made any monetary
8 contribution intended to fund the preparation or submission of this brief.

9 Counsel for Petitioners Pasadena Hospital Association Ltd. and Cedars-Sinai Health
10 System consent to the filing of this application and proposed *amicus curiae* brief. Counsel for
11 Respondents California Department of Justice and Rob Bonta, in his official capacity as Attorney
12 General of California, take no position on the filing of this application and proposed *amicus curiae*
13 brief.

14 For the foregoing reasons, *amici* respectfully request that the Court grant this application
15 to file the attached *amicus curiae* brief in support of Petitioners' petition for writ of mandate.

16 Dated: May 27, 2021

WILSON SONSINI GOODRICH & ROSATI
Professional Corporation

18 By: /s/ Olivia M. Kim
Olivia M. Kim

19 *Attorneys for Amici Curiae American Hospital*
20 *Association, Association of American Medical*
21 *Colleges, and California Hospital Association*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

TABLE OF CONTENTS

	<u>Page</u>
I. Introduction	9
II. Affiliations Between Community Hospitals and Academic Medical Centers Bring Substantial Benefits to Patients	9
A. Operating Expense Reductions	10
B. Capital Investments and Resource Allocation Efficiencies	11
C. Quality Improvements	13
III. The OCAG Conditions Are Based on an Affidavit from Dr. Vistnes that Fails to Apply Established Economic Methodologies	13
A. Dr. Vistnes Concedes that He Does Not Know Whether the Transaction Is Likely to Harm Patients or Communities.....	14
B. Dr. Vistnes’s Cross-Market Effects Theory Provides No Reliable Basis for this Court to Reject Petitioners’ Challenge to the OCAG’s Decision.....	14
1. Dafny, Ho, and Lee – Cross-Market Common Customers	14
2. Lewis and Pflum – Bargaining Knowledge	18

TABLE OF AUTHORITIES

Page(s)

CASES

1		
2		
3		
4	<i>Atlantic Richfield Co. v. USA Petroleum Co.</i> ,	
5	495 U.S. 328 (1990)	18
6	<i>Buck v. Ford Motor Co.</i> ,	
7	810 F. Supp. 2d 815 (N.D. Ohio 2011)	16
8	<i>Fed. Trade Comm’n v. Thomas Jefferson Univ.</i> ,	
9	No. 2:20-cv-01113, 2020 U.S. Dist. LEXIS 229735	
10	(E.D. Pa. Dec. 8, 2020)	16
11	<i>Flagship Theatres of Palm Desert, LLC v. Century Theatres, Inc.</i> ,	
12	55 Cal. App. 5th 381 (Cal. Ct. App. 2020)	15
13	<i>Forsyth v. Humana, Inc.</i> ,	
14	114 F.3d 1467 (9th Cir. 1997)	16
15	<i>Gen. Elec. Co. v. Joiner</i> ,	
16	522 U.S. 136 (1997)	17
17	<i>New York v. Deutsche Telekom AG</i> ,	
18	439 F. Supp. 3d 179 (S.D.N.Y. 2020)	15
19	<i>Olive v. Gen. Nutrition Ctrs., Inc.</i> ,	
20	30 Cal. App. 5th 804 (Cal. Ct. App. 2018)	16
21	<i>Roth v. Rhodes</i> ,	
22	25 Cal. App. 4th 530 (Cal. Ct. App. 1994)	17
23	<i>Sargon Enters., Inc. v. Univ. of S. Cal.</i> ,	
24	55 Cal. 4th 747 288 P.3d 1237 (2012)	13, 16, 17
25	<i>Sidibe v. Sutter Health</i> ,	
26	4 F. Supp. 3d 1160 (N.D. Cal. 2013)	16
27	<i>United States v. Marine Bancorporation, Inc.</i> ,	
28	418 U.S. 602 (1974) (Clayton Act § 7 “deals in probabilities, not ephemeral possibilities”)	14

STATUTES

1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24	15 U.S.C. § 18	14
25	15 U.S.C. § 1	14
26	Evidence Code section 801	13
27	Evidence Code section 802	13
28		

MISCELLANEOUS

1

2 Am. Hospital Assoc.,
3 Underpayment by Medicare and Medicaid Fact Sheet (Jan. 2021) 10

4 Keith Brand & Ted Rosenbaum,
5 A Review of the Economic Literature on Cross-Market
6 Health Care Mergers, 82 Antitrust L.J. 533 (2019) 18

7 Gay Casey et al.,
8 Berkeley Research Grp., Hospital Mergers and Acquisitions —
9 Studying Successful Outcomes (2020) 13

10 Leemore Dafny, Kate Ho & Robin S. Lee,
11 The Price Effects of Cross-Market Mergers:
12 Theory and Evidence from the Hospital Industry,
13 50 RAND J. Econ. 286 (2019) 14, 15

14 Thomas Enders (Manatt Health) & Joanne Conroy
15 (Assoc. Am. Med. Colleges), Advancing the Academic
16 Health System for the Future (2014)..... 12

17 Margaret E. Guerin-Calvert & Jen A. Maki,
18 FTI Consulting, Hospital Realignment: Mergers
19 Offer Significant Patient and Community Benefits (2014)..... 10

20 Margaret E. Guerin-Calvert & Jen A. Maki,
21 FTI Consulting, Hospital Realignment: Mergers
22 Offer Significant Patient and Community Benefits (2014)..... 11, 12

23 Clark Knapp et al.,
24 Deloitte Ctr. for Health Solutions, Hospital M&A:
25 When Done Well, M&A Can Achieve Valuable Outcomes (2017) 11, 13

26 Matthew S. Lewis & Kevin E. Pflum,
27 Hospital Systems and Bargaining Power: Evidence from
28 Out-of-Market Acquisitions. 48 RAND J. Econ. 579 (2017) 17

Monica Noether & Sean May,
Charles River Assocs., Hospital Merger Benefits:
Views from Hospital Leaders and Econometric Analysis (2017)..... 10, 11, 12

Monica Noether, Sean May & Ben Stearns,
Charles River Assocs., Hospital Merger Benefits:
Views from Hospital Leaders and Econometric Analysis –
An Update (2019)..... 10, 11, 12, 13

Michael J. Perry & Matthew B. Adler,
Antitrust Enforcement Policy for Cross-Market Health
Care Mergers, 83 Antitrust L.J. 483 (2020) 15, 18

Matt Schmitt,
Do Hospital Mergers Reduce Costs?, 52 J. Health Econ. 74 (2017) 11

28

1 Gregory Vistnes & Yianis Sarafidis,
2 Cross-Market Hospital Mergers: A Holistic Approach,
79 Antitrust L.J. 253 (2013)..... 13, 15, 17

3 Gregory Vistnes,
4 Competitive Effects Analysis (Dec. 20, 2020)..... 9, 14, 15, 16, 17

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

1 **I. Introduction**

2 The onerous conditions that the Office of the California Attorney General (“OCAG”) seeks
3 to impose on the affiliation between Cedars-Sinai Health System (“CSHS”) and Pasadena Hospital
4 Association (“Huntington”) (the “Affiliation”) are arbitrary and unwarranted. The expert on which
5 the OCAG exclusively relies for its decision concedes in his affidavit that (1) CSHS and
6 Huntington do *not* materially compete; and (2) he has not determined that the transaction is likely
7 to produce anticompetitive effects. Gregory Vistnes, Competitive Effects Analysis 2-3 (Dec. 20,
8 2020) (AG Decision, ex. 4) (“Vistnes Report”). Nor could the expert make this determination
9 because he also concedes that he has not tried to analyze whether the transaction will produce
10 benefits for consumers. *Id.* at 1 n.3.

11 The OCAG and its expert’s sole basis for the onerous conditions is a novel “theory” of
12 “cross-market” effects. Moreover, there is no established methodology to apply the theory to a
13 specific merger or accepted principles to cabin its use. And the theory is so malleable that the
14 OCAG could use it to block or modify Huntington’s affiliation with many major hospital systems.
15 If approved by this Court, such wide-ranging, arbitrary authority would produce substantial
16 uncertainty in the hospital sector and deter transactions that would benefit patients and
17 communities throughout California.

18 **II. Affiliations Between Community Hospitals and Academic Medical Centers Bring**
19 **Substantial Benefits to Patients**

20 For decades, hospitals and health professionals have worked to improve patient outcomes
21 and lower the costs of care by reducing fragmentation in the delivery of health care. Affiliations
22 with hospital systems are effective ways for community hospitals to lower costs and improve
23 clinical care while preserving access to care in underserved communities. Huntington is seeking
24 these benefits through the Affiliation with CSHS, but the OCAG’s action puts the Affiliation and
25 other beneficial transactions in California at risk. *See* Compl. ¶ 48 (quoting the OCAG’s analysis
26 that Huntington would “be at a competitive disadvantage” if it remains a standalone hospital
27 compared to “more integrated health care systems”).

28 In contrast to the theoretical and speculative harms posited by the OCAG’s economist,

1 economic research supports Petitioners’ position that the planned Affiliation will expand access
2 and improve patient care for the Los Angeles communities the facilities serve. The research shows
3 that community hospitals partnering with hospital systems provide measurable benefits to patients:
4 lower healthcare costs, improved patient care, and better access to providers. *See* Monica Noether,
5 Sean May & Ben Stearns, Charles River Assocs., Hospital Merger Benefits: Views from Hospital
6 Leaders and Econometric Analysis – An Update 1 (2019).¹

7 **A. Operating Expense Reductions**

8 Decreasing inpatient admissions and lower government reimbursement rates challenge
9 community hospitals’ financial stability, potentially reducing access to care for their communities.
10 Huntington is similarly positioned, with negative operating income over the past five years
11 according to the OCAG’s contracted analysis. Compl. ¶¶ 5, 46. Over the period 2004 to 2014,
12 inpatient admissions at community hospitals fell by 5.8% and the number of inpatient days
13 declined by 8.7%. Monica Noether & Sean May, Charles River Assocs., Hospital Merger Benefits:
14 Views from Hospital Leaders and Econometric Analysis 3 (2017).² At the same time, Medicare
15 and Medicaid reimbursement rates continue to fall below hospitals’ actual costs: combined
16 underpayments were \$75.8 billion in 2019. Am. Hospital Assoc., Underpayment by Medicare and
17 Medicaid Fact Sheet (Jan. 2021).³

18 Affiliations with larger hospital systems can provide community hospitals like Huntington
19 the scale and resources to decrease costs. Increased administrative and operating efficiencies and
20 reduction of redundant services contribute to merger-specific reductions in the cost of care. *See*
21 Margaret E. Guerin-Calvert & Jen A. Maki, FTI Consulting, Hospital Realignment: Mergers Offer
22 Significant Patient and Community Benefits 2 (2014).⁴ Hospital mergers between 2009 and 2014
23 “were associated with a 2.5 percent reduction in operating expense per admission at the acquired
24 hospitals.” Noether & May at 14. Extending the analysis through 2017 found a 2.3% reduction

25 _____
26 ¹ <https://media.crai.com/wp-content/uploads/2020/09/16164319/CRA-report-merger-benefits-2019-FINAL.pdf>

27 ² <https://media.crai.com/wp-content/uploads/2020/09/16164320/Hospital-Merger-Full-Report-FINAL-1.pdf>

28 ³ <https://www.aha.org/system/files/media/file/2020/01/2020-Medicare-Medicaid-Underpayment-Fact-Sheet.pdf>

⁴ https://www.ftc.gov/system/files/documents/public_comments/2014/05/00202-90180.pdf

1 in operating expenses per admission at acquired hospitals, with hospital systems reporting total
2 expense savings of about 1.5% to 3.5% through consolidation of administrative and supply chain
3 operations. Noether, May & Stearns at 1, 3; *see also* Matt Schmitt, Do Hospital Mergers Reduce
4 Costs?, 52 J. Health Econ. 74 (2017) (finding statistically significant cost reductions at acquired
5 hospitals averaging between 4% and 7%).⁵

6 Additional substantial savings come from improved IT systems and advanced data
7 analytics. Consolidated hospital systems can better invest in IT infrastructure for both clinical and
8 financial data that they utilize to identify best practices for quality care that is more cost-effective
9 and streamlined. Noether, May & Stearns at 4. These data systems have substantial but largely
10 fixed costs, making them effectively inaccessible to independent hospitals. Noether & May at 5.
11 Hospital systems can spread the costs over a larger patient population while also performing more
12 sophisticated analyses, given the larger patient database, to identify patterns and improve care.
13 Noether, May & Stearns at 3-4. That is the case for the planned Affiliation: Petitioners project
14 anticipated cost savings from combined administrative and backend infrastructure, shared
15 electronic medical records system, joint purchasing, and research collaborations. *See* Compl. ¶ 4.

16 Moreover, hospitals realize the cost benefits of mergers quickly, with hospitals largely
17 reporting reduced operating expenses one year after the merger. Clark Knapp et al., Deloitte Ctr.
18 for Health Solutions, Hospital M&A: When Done Well, M&A Can Achieve Valuable Outcomes
19 5 (2017).⁶ And the benefits last, with one study finding cost savings still evident four years after
20 consummation of the merger, and another finding lower cost growth rates and lower price growth
21 rates at merging hospitals compared to non-merging hospitals over an extended period. Guerin-
22 Calvert & Maki at 18.

23 **B. Capital Investments and Resource Allocation Efficiencies**

24 Financially distressed community hospitals often cannot recruit clinical staff, upgrade
25 technology, or offer specialty services. Noether, May & Stearns at 5. Nearly half of hospitals
26 report putting capital projects on hold. Guerin-Calvert & Maki at 11. Like CSHS, acquiring

27 ⁵ http://www.anderson.ucla.edu/Documents/areas/fac/strategy/Schmitt_HospitalMergersCosts.pdf

28 ⁶ <https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-hospital-mergers-and-acquisitions.pdf>

1 hospitals often provide capital infusions to community hospitals to address funding issues, as
2 evidenced by the almost 80% of respondents in one survey who reported significant capital
3 investments in the acquired hospital. Knapp et al. at 3. These capital infusions allow the acquired
4 hospital to restart planned projects or undertake new investments in staff, technology, or facilities,
5 not only preventing closure of the hospital or certain service lines but possibly improving quality
6 of service and patient welfare. Guerin-Calvert & Maki at 16, 19.

7 The Affiliation will provide beneficial capital to Huntington. The Petitioners' filings state
8 that CSHS will provide up to \$300 million of non-operating cash funding for overdue capital
9 projects to improve patient care, safety, and access, including retrofitting buildings, expanding
10 ambulatory services capabilities, implementing a new electronic health records system, and
11 recruiting physicians to maintain and improve service levels. Compl. ¶¶ 5, 43; *see id.* ¶ 113
12 (improved bond rating for Huntington conditional on the Affiliation).

13 Hospital transactions can also help improve resource allocation and address resource
14 constraints, including physical space, capital, and personnel. Guerin-Calvert & Maki at 15. With
15 reduced patient volumes, community hospitals often have excess capacity, which can impair their
16 financial performance and access to capital. Noether & May at 6. Academic medical centers, in
17 contrast, often have capacity constraints because communities look to them not only for tertiary
18 and quaternary services—including neurosurgery, severe burn treatment, cancer care, advanced
19 neonatology, and transplantation—but also for less specialized services. *Id.*

20 Mergers and affiliations realign these resources to better meet community needs. Guerin-
21 Calvert & Maki at 14. Integration of lower-cost community hospitals with high-throughput
22 academic medical centers allows the system to optimize service mix to the most appropriate and
23 cost-effective settings of care. Thomas Enders (Manatt Health) & Joanne Conroy (Assoc. Am.
24 Med. Colleges), *Advancing the Academic Health System for the Future* 26 (2014).⁷ Patients who
25 need less complex services would be treated at community hospitals, which eases capacity
26 constraints at the academic medical center, drives down costs, and often provides a more

27 _____
28 ⁷ [https://www.manatt.com/uploadedFiles/Content/2_Our_People/Enders_Thomas/
AdvancingtheAcademicHealthSystemfortheFuture_AAMC_Mar2014_Paper.PDF](https://www.manatt.com/uploadedFiles/Content/2_Our_People/Enders_Thomas/AdvancingtheAcademicHealthSystemfortheFuture_AAMC_Mar2014_Paper.PDF)

1 convenient location for the patients. *See id.* at 6, 26; Noether & May at 6. The academic medical
2 center could then devote existing space for tertiary and quaternary services not available at
3 community hospitals without new capital investments. Noether, May & Stearns at 6.

4 **C. Quality Improvements**

5 Finally, mergers and affiliations provide community hospitals the scale needed to utilize
6 sophisticated data analytics, identify best practices, and implement innovations such as
7 telemedicine that improve access and patient outcomes. *Id.* at 4-5. The Petitioners' anticipated
8 benefits from sharing best practices, new technologies, population health programs, and clinical
9 training are empirically supported by prior hospital transactions. *See* Compl. ¶¶ 4, 50. Researchers
10 found statistically significant improvements in the 30-day readmission rates and mortality rates at
11 acquired hospitals, using CMS data for heart attack, heart failure, and pneumonia patients.
12 Noether, May & Stearns at 12. Other quality improvements following a hospital acquisition
13 include increased HCAHPS scores,⁸ reduced readmissions, reduced appointment wait times, and
14 reduced mortality. Knapp et al. at 8. And acquired hospitals improved their Leapfrog Hospital
15 Safety Grade by a median of one grade category. Gay Casey et al., Berkeley Research Grp.,
16 Hospital Mergers and Acquisitions — Studying Successful Outcomes 7 (2020).⁹

17 **III. The OCAG Conditions Are Based on an Affidavit from Dr. Vistnes that Fails to Apply** 18 **Established Economic Methodologies**

19 The OCAG's sole basis for its onerous conditions is an affidavit prepared by Dr. Vistnes
20 of Charles River Associates. Dr. Vistnes hypothesizes a loss of competition from the novel theory
21 of "cross-market" effects. Critical for assessing the arbitrariness of the OCAG's decision is that
22 neither Dr. Vistnes nor any of the theory's proponents have developed an economic methodology
23 to determine if the hypothesized effects are likely to occur for a given transaction. This gap is
24 disqualifying. As Dr. Vistnes has written, there is no evidence that "most (or even many) [cross-
25 market] mergers should raise competitive concerns or a presumption of competitive harm."
26

27 ⁸ The Hospital Consumer Assessment of Healthcare Providers and Systems survey ("HCAHPS")
28 is a national, standardized, publicly reported survey of patients' perspectives of hospital care
administered by CMS.

⁹ <https://www.thinkbrg.com/insights/publications/hospital-mergers-acquisitions-juniper/>

1 Gregory Vistnes & Yianis Sarafidis, Cross-Market Hospital Mergers: A Holistic Approach, 79
2 Antitrust L.J. 253, 259 (2013).¹⁰ Indeed, given the lack of an implementing methodology for the
3 cross-market effects theory, there is doubt that Dr. Vistnes’s opinions would be admissible under
4 Evidence Code sections 801 and 802. *See Sargon Enters., Inc. v. Univ. of S. Cal.*, 55 Cal. 4th 747,
5 769 (2012) (“Expert testimony must not be speculative . . .”).

6 **A. Dr. Vistnes Concedes that He Does Not Know Whether the Transaction Is**
7 **Likely to Harm Patients or Communities**

8 Dr. Vistnes concedes that “the proposed affiliation is unlikely to significantly reduce direct
9 competition” because the parties generally do not compete with each other. Vistnes Report at 2.
10 This finding ends most objective competition-based investigations of a transaction because the
11 purpose of the antitrust laws is to prevent reductions in competition. *See* 15 U.S.C. §§ 1 & 18.
12 The Federal Trade Commission apparently agreed because it rapidly approved the Affiliation.

13 Dr. Vistnes nonetheless asserts that the Affiliation “pos[es] a real *risk* of cross-market
14 effects” although he concedes in the same sentence that “the *likelihood*, and likely *magnitude*, of
15 cross-market effects is unclear.” Vistnes Report at 3. In other words, Dr. Vistnes admits that he
16 does not know the *probability* that the transaction will harm anyone, the *amount* of any potential
17 harm, or the *amount* of offsetting benefits. *See id.* at 1 n.3. These concessions are fatal as a matter
18 of antitrust law. *See, e.g., United States v. Marine Bancorporation, Inc.*, 418 U.S. 602, 622-23
19 (1974) (Clayton Act § 7 “deals in probabilities, not ephemeral possibilities”). And they should be
20 fatal here because they reflect the arbitrariness of the OCAg’s decision.

21 **B. Dr. Vistnes’s Cross-Market Effects Theory Provides No Reliable Basis for this**
22 **Court to Reject Petitioners’ Challenge to the OCAg’s Decision**

23 Dr. Vistnes attempts to leverage the few academic papers that have analyzed the cross-
24 markets theory to bolster his speculative opinions. His efforts are deficient.

25 **1. Dafny, Ho, and Lee – Cross-Market Common Customers**

26 Dr. Vistnes heavily relies on a 2019 paper by Dafny, Ho, and Lee (“Dafny Paper”). The
27

28 ¹⁰ <https://media.crai.com/sites/default/files/publications/Cross-market-hospital-mergers-a-holistic-approach.pdf>

1 authors use a dataset of 144 ostensible cross-market hospital transactions and find that prices were
2 on average 7% to 10% higher for those hospitals than prices for hospitals in a control group. The
3 Dafny Paper¹¹ proposes that the price effects *might* be caused by the presence of “common
4 customers”: employers with employees in multiple antitrust geographic markets who choose one
5 health plan for all their employees and so want a network that includes hospitals in the different
6 geographic markets. Dafny Paper at 294. The authors posit that combining non-competing
7 hospitals from different geographic markets could conceptually allow the merged entities to raise
8 prices to insurers who serve such common customers. *Id.* at 294-95.

9 The Dafny Paper has significant limitations, as other economists have observed. *First*, the
10 Dafny Paper is “largely agnostic” as to *why* or *how* the cross-market mergers produced the alleged
11 price effects. Vistnes Report at 19; *see* Dafny Paper at 315 (citing the need for research to model
12 the “links between and among insurance choice, insurance competition, and hospital-insurer
13 bargaining”). This gap should make the theory unusable here. *See New York v. Deutsche Telekom*
14 *AG*, 439 F. Supp. 3d 179, 245 (S.D.N.Y. 2020) (“Anticompetitive . . . effects of a merger do not
15 just ‘happen’; they are not self-executing outcomes spontaneously set in motion . . .”).

16 *Second*, the theory requires that the merging hospitals operate in distinct geographic
17 markets. But the Dafny Paper uses only rough proxies to identify transactions that might involve
18 facilities in different markets. This is insufficient in antitrust cases and reflects the potential
19 arbitrariness of applying the theory here. *See Flagship Theatres of Palm Desert, LLC v. Century*
20 *Theatres, Inc.*, 55 Cal. App. 5th 381, 413 (Cal. Ct. App. 2020) (to assess “[d]irect evidence of
21 anticompetitive effects . . . we must first define the relevant market” (quotation omitted)).

22 *Third*, the Dafny Paper focuses only on nominal prices charged to insurance companies.
23 Like Dr. Vistnes here, the authors did not attempt to analyze whether the transactions at issue
24 would improve clinical outcomes, provide cost savings, or generate other benefits to *patients*. *See*
25 Dafny Paper at 303-04, 310.

26 *Fourth*, and critically, the Dafny Paper provides no *methodology* to analyze a specific
27

28 ¹¹ Leemore Dafny, Kate Ho & Robin S. Lee, The Price Effects of Cross-Market Mergers: Theory
and Evidence from the Hospital Industry, 50 RAND J. Econ. 286 (2019).

1 merger using the cross-market effects theory, a fact that Dr. Vistnes concedes: “the [common
2 customer] . . . cross-market theories are limited with respect to their ability to identify which
3 particular cross-market mergers are likely to cause harm.” Vistnes Report at 21 n.82; Vistnes &
4 Sarafidis at 259 n.24 (“We believe that given the premature state of [cross-market] ‘theory’ . . . we
5 would be overreaching if we used our two models to predict where and when cross-market mergers
6 may be problematic and to identify the determinants of the magnitude of the potential problem.”);
7 *see also* Michael J. Perry & Matthew B. Adler, Antitrust Enforcement Policy for Cross-Market
8 Health Care Mergers, 83 Antitrust L.J. 483, 495 (2020) (quoting Dr. Vistnes’s presentation on
9 cross-market effects to the American Health Lawyers Association, where he cautioned it “appears
10 to be more difficult to prove the theory than to tell the story”).¹²

11 The lack of a rigorous implementing methodology would make the cross-market theory
12 inadmissible in many proceedings and warrants rejecting the OCAG’s reliance on it here. *See,*
13 *e.g., Sargon Enters.*, 55 Cal. 4th at 781 (affirming exclusion of expert testimony because of “lack
14 of sound methodology in the expert’s testimony for determining what the future would have
15 brought”); *Olive v. Gen. Nutrition Ctrs., Inc.*, 30 Cal. App. 5th 804, 820 (Cal. Ct. App. 2018)
16 (affirming exclusion when expert opined on causal connection “without identifying any reliable
17 evidence linking” the events); *Buck v. Ford Motor Co.*, 810 F. Supp. 2d 815, 825-26 (N.D. Ohio
18 2011) (excluding expert testimony based on an “untested” hypothesis because “even if plausible,”
19 it was “not reliably applied”).

20 Dr. Vistnes tries to overcome the lack of an established implementing methodology for the
21 common customer theory by identifying several self-selected “plus factors” that he claims provide
22 a “rationale for intervening here but not in every cross-market merger or affiliation.” Vistnes
23 Report at 21. His first “plus factor” of market power is actually a requirement for the common
24 customer theory to apply in the first place, not an indicator that cross-market effects are likely. *Id.*
25 at 29 n.110 (“market power at both the acquired and acquiring hospital are required”). Regardless,
26 Dr. Vistnes has not done a rigorous market power analysis. He lacks verifiable and quantitative
27

28 ¹² https://www.americanbar.org/content/dam/aba/publishing/antitrust_law_journal/alj-832/alj-83-2-perry-adler.pdf

1 direct evidence of market power, *see Forsyth v. Humana, Inc.*, 114 F.3d 1467, 1475 (9th Cir. 1997)
2 (“Direct proof of market power may be shown by evidence of restricted output and
3 supracompetitive prices.”), and has not properly defined a market. *See Sidibe v. Sutter Health*, 4
4 F. Supp. 3d 1160, 1180 (N.D. Cal. 2013) (“Plaintiffs’ conclusory allegations do not establish direct
5 evidence of market power. Thus, they needed to define the relevant market.”).

6 Underscoring the lack of fairness in the OCAg’s process, Dr. Vistnes relies on conclusory
7 snippets of his private discussions with health insurers that are not reliable economic evidence of
8 a relevant market or market power. *See Fed. Trade Comm’n v. Thomas Jefferson Univ.*, No. 2:20-
9 cv-01113, 2020 U.S. Dist. LEXIS 229735, at *5 (E.D. Pa. Dec. 8, 2020) (“[The insurers’]
10 conclusory assertions that they would have to succumb to a price increase for services in the
11 Government’s proposed markets instead of looking to healthcare providers outside those markets
12 are not credible.”). As Dr. Vistnes has written, asking a health plan representative if purported
13 network holes caused by a merger would disproportionately affect the plan’s profitability is
14 “unlikely to yield a meaningful response.” Vistnes & Sarafidis at 280.

15 In addition, Dr. Vistnes tries to assess market power by looking at the parties’ shares in
16 various zip codes. But because Dr. Vistnes does not define relevant markets and the parties’
17 competitors in those markets, his “share” analysis is uninformative and inconsistent with standard
18 economic methodology. *See Roth v. Rhodes*, 25 Cal. App. 4th 530, 542 (Cal. Ct. App. 1994)
19 (market power can be inferred from “possession of a substantial percentage of the sales in a market
20 carefully defined in terms of both product and geography” (quotation omitted)).

21 Dr. Vistnes also attempts to bolster the common customer theory by citing the views of
22 health insurance companies about the presence of common customers, payor concerns, and
23 purportedly high Cedars-Sinai Medical Center prices. None of this is verifiable or even testable
24 because many of his assertions are based on non-public interviews with insurance companies.
25 Courts rarely credit the unverified say-so of an expert about the existence of factual information.
26 *See Gen. Elec. Co. v. Joiner*, 522 U.S. 136, 146 (1997) (a court need not “admit opinion evidence
27 that is connected to existing data only by the *ipse dixit* of the expert”); *Sargon Enters.*, 55 Cal. 4th
28 at 770 (expert opinions may not be based on “assumptions of fact without evidentiary support”).

1 As Dr. Vistnes cautions: payor concerns “should not be taken at face value” and should not replace
2 “a more thorough competitive effects analysis.” Vistnes Report at 28-29.

3 2. Lewis and Pflum – Bargaining Knowledge

4 Dr. Vistnes also discusses a 2017 article by Lewis and Pflum, which also uses a regression
5 to find price increases allegedly attributable to cross-market hospital transactions.¹³ In contrast to
6 the Dafny Paper, Lewis and Pflum attribute the price increases to the possible increased bargaining
7 sophistication of the smaller acquired hospitals. In other words, the authors purport to find price
8 increases that result from massive health insurance companies being less able to use their superior
9 knowledge to take advantage of community hospitals in rate negotiations. *See* Keith Brand & Ted
10 Rosenbaum, A Review of the Economic Literature on Cross-Market Health Care Mergers, 82
11 Antitrust L.J. 533, 543 (2019) (explaining the possible price effect in terms of the hospital’s ability
12 to extract a greater share of the negotiating surplus from the more sophisticated insurer).¹⁴

13 Even if true, such price effects are not anticompetitive because increased bargaining
14 knowledge is not a reduction in competition. *See generally Atlantic Richfield Co. v. USA*
15 *Petroleum Co.*, 495 U.S. 328, 344 (1990) (antitrust injury must “stem[] from a competition-
16 *reducing* aspect or effect of the defendant’s behavior”); Perry & Adler at 499, 502.

17 Dr. Vistnes’s reliance on the Lewis and Pflum paper also reflects the arbitrariness of his
18 conclusions and uncertainty that would follow from this Court endorsing his approach. As other
19 economists have observed, Lewis and Pflum focus on the nebulous concept of improved
20 bargaining knowledge rather than an “identifiable reduction in competition, thus there are no
21 effective limiting principles on how [their] theory could be applied in practice.” Perry & Adler at
22 499; *see* Brand & Rosenbaum at 548 (discussing the Dafny and Lewis and Pflum papers and
23 finding no “good evidence on which mechanisms are most relevant and, therefore, how to best
24 predict ex ante which mergers are likely to be problematic”).¹⁵

26 ¹³ Matthew S. Lewis & Kevin E. Pflum, Hospital Systems and Bargaining Power: Evidence from
27 Out-of-Market Acquisitions. 48 RAND J. Econ. 579 (2017).

28 ¹⁴ http://www.tedrosenbaum.org/uploads/1/4/3/6/14360754/brand_rosenbaum_alj_82-2_final.pdf

¹⁵ Dr. Vistnes also mentions a theory of harm based on antitrust “tying” law but presents no
academic research studying cross-market effects in this context or economic analysis of the
Affiliation using a “traditional tying” framework.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dated: May 27, 2021

WILSON SONSINI GOODRICH & ROSATI
Professional Corporation

By: /s/ Olivia M. Kim

Olivia M. Kim, State Bar No. 228382
WILSON SONSINI GOODRICH & ROSATI
Professional Corporation
633 West Fifth Street, Suite 1550
Los Angeles, CA 90071-2027
Telephone: (323) 210-2900
Facsimile: (866) 974-7329
Email: okim@wsgr.com

*Attorneys for Amici Curiae American Hospital
Association, Association of American Medical
Colleges, and California Hospital Association*

1 **PROOF OF SERVICE**

2 I, Amanda Navarro, declare:

3 I am employed in Los Angeles County, State of California. I am over the age of 18 years
4 and not a party to the within action. My business address is Wilson Sonsini Goodrich & Rosati,
5 633 West Fifth Street, Suite 1550, Los Angeles, CA 90071-2027.

6 On this date, I served:

7 **APPLICATION FOR LEAVE TO FILE AMICUS CURIAE BRIEF BY THE AMERICAN**
8 **HOSPITAL ASSOCIATION, ASSOCIATION OF AMERICAN MEDICAL COLLEGES,**
9 **AND CALIFORNIA HOSPITAL ASSOCIATION AND [PROPOSED] BRIEF IN**
10 **SUPPORT OF PETITIONERS**

11 on the interested parties to this action by delivering thereof in a sealed envelope addressed to
12 each of said interested parties at the following address(es):

13 By placing the document(s) in a sealed envelope for collection and mailing with
14 the United States Postal Service on this date to the following person(s):

15 Seth E. Goldstein – State Bar No. 238228
16 OFFICE OF THE ATTORNEY GENERAL
17 1300 I Street, Suite 125
18 P.O. Box 944255
19 Sacramento, CA 94244-2550
20 (916) 210-6063
21 Seth.Goldstein@doj.ca.gov

*Counsel for Defendants California
Department of Justice and Rob Bonta, in
his official capacity as Attorney General
of California*

19 MARGARET H. WARNER
20 mwarner@mwe.com
21 PAUL W. HUGHES
22 phughes@mwe.com
23 MCDERMOTT WILL & EMERY LLP
24 500 North Capitol Street NW
25 Washington, DC 20001
26 Telephone: (202) 756-8000

*Counsel for Plaintiffs Cedars-Sinai
Health
System and Pasadena Hospital
Association
Ltd. d/b/a Huntington Hospital*

24 ANDREW BAUM - State Bar No. 190397
25 abaum@glaserweil.com
26 GLASER WEIL FINK HOWARD
27 AVCHEN & SHAPIRO LLP
28 10250 Constellation Boulevard, 19th Floor
Los Angeles, California 90067
Telephone: (310) 553-3000

1 Jean Tom – State Bar No. 304393
2 DAVIS WRIGHT TREMAINE LLP
3 505 Montgomery Street, Suite 800
4 San Francisco, CA 94111
5 (415) 276-6538

*Counsel for Plaintiff Pasadena Hospital
Association Ltd. d/b/a Huntington
Hospital*

6 I am readily familiar with Wilson Sonsini Goodrich & Rosati’s practice for collection and
7 processing of documents for delivery according to instructions indicated above. In the ordinary
8 course of business, documents would be handled accordingly.

9 I declare under penalty of perjury under the laws of the State of California that the
10 foregoing is true and correct. Executed at Los Angeles, California on May 27, 2021.

11 /s/ Amanda Navarro
12 Amanda Navarro